A patient presented with loss of consciousness and conversion. During an exercise test, catecholaminergic polymorphic ventricular tachycardia (CPVT) resulted in cardiac arrest. He started taking medication (a beta-blocker and flecainide) and an implantable cardioverter defibrillator (ICD) was inserted, but the ventricular tachycardia did not resolve. Left cardiac sympathetic denervation (LCSD) was then performed under general anesthesia, and the patient was discharged on the second postoperative day without complications. One month after the operation, no shock had been administered by the ICD, and an exercise stress test did not induce ventricular tachycardia. Although beta-blockers are the gold standard of therapy in patients with CPVT, thoracoscopic LCSD is safe and can be an effective alternative treatment option for patients with intractable CPVT. 
A patient presented with loss of consciousness and conversion. During an exercise test, catecholaminergic polymorphic ventricular tachycardia (CPVT) resulted in cardiac arrest. He started taking medication (a beta-blocker and flecainide) and an implantable cardioverter defibrillator (ICD) was inserted, but the ventricular tachycardia did not resolve. Left cardiac sympathetic denervation (LCSD) was then performed under general anesthesia, and the patient was discharged on the second postoperative day without complications. One month after the operation, no shock had been administered by the ICD, and an exercise stress test did not induce ventricular tachycardia. Although beta-blockers are the gold standard of therapy in patients with CPVT, thoracoscopic LCSD is safe and can be an effective alternative treatment option for patients with intractable CPVT. the operation, no shocks had been administered by the ICD, and an exercise stress test did not induce VT (Fig. 1) .
DISCUSSION
CPVT was first described in 1975 [1] , and is characterized by bidirectional or polymorphic ventricular tachycardia in-
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− 223 − duced by increased sympathetic activity secondary to physical exercise or emotional stress [2] . Genetic studies in the past decade have revealed mutations in two genes (RYR2, CASQ2) [3] that are known to be associated with abnormal intracellular calcium handling and cause adrenergically mediated polymorphic ventricular tachyarrhythmias by delayed afterdepolarizations and triggered activity [4] .
CPVT presents clinically with syncope, aborted cardiac arrest, or sudden cardiac death, all of which are triggered by physical or emotional stress. Moreover, symptoms often develop at a young age. In some cases, sudden death is the first manifestation [5] . Therefore, the accurate and early diagnosis of CPVT is critical for achieving the best possible clinical results in these patients. Reproducibility of the typical arrhythmia by provocative testing, such as an exercise stress test or an isoproterenol infusion test, is important in establishing the diagnosis [5] . However, CPVT-related syncopal episodes may include seizures involving urinary or fecal incontinence, and usually present with normal ECG findings.
Therefore, the average delay in diagnosis has been reported to be as high as 2.0±0.8 years after the manifestation of the first symptoms [6] . Our patient's condition was initially misdiagnosed as epilepsy, and antiepileptic medication was administered for four years, which resulted in a delayed diagnosis of CPVT.
Beta-blockers are the first-line therapy for CPVT, and they are known to provide most patients with sufficient protection.
Since fatal ventricular storms can be initiated by shocks from an ICD that trigger subsequent catecholamine release [7] , ICD placement should only be considered in patients who have been resuscitated after cardiac arrest and who have experienced recurring syncope or sustained VT despite beta-blocker therapy [8] . Other pharmacologic treatments (sodium channel blockers, amiodarone, verapamil) have been shown to have an additive benefit in combination with beta-blockers [5] . LCSD can be considered when ventricular arrhythmias remain uncontrolled by beta-blockers and other additive drug therapies. After Wilde et al. [2] first reported that LCSD is an effective therapy for CPVT, several other researchers have confirmed that LCSD is highly effective and safe in severely affected CPVT patients [9] . Moreover, Hofferberth et al. [10] presented the results of thoracoscopic Clinical evidence has indicated that LCSD may have a role in treating patients with channelopathies such as long QT syndrome, previous myocardial infarction, and CPVT [11] .
In summary, CPVT is a genetic disorder involving intracellular calcium handling that leads to adrenergically-mediated life threatening ventricular tachyarrhythmias. Although beta-blockers are the gold standard of therapy in patients with CPVT, thoracoscopic LCSD is safe and can be an effective alternative treatment option. LCSD is a particularly important option for patients for whom beta-blockers are contraindicated and in patients who experience recurrent ICD shocks despite optimal treatment with medication.
